Nvidia shares pop as analysts dismiss AI bubble concerns
Charles River Laboratories International, Inc. (NYSE:CRL) announced Monday that the U.S. Securities and Exchange Commission’s Division of Enforcement has concluded its investigation into the company regarding the sourcing of non-human primates and related disclosures. According to a statement from the company, the SEC notified Charles River Laboratories on Thursday that, based on the information available, it does not intend to recommend any enforcement action against the company.
The inquiry began in May 2023, when Charles River Laboratories received a request from the SEC’s Enforcement Division to voluntarily provide information. This request was later expanded to include a document subpoena and additional inquiries, primarily focused on the sourcing of non-human primates and related company disclosures. In response, the company’s Audit Committee retained independent counsel to conduct its own investigation into the issues raised.
Both the SEC’s investigation and the company’s independent review have now concluded. Charles River Laboratories stated that its internal investigation resulted in no material findings.
The announcement is based on a press release statement included in the company’s Form 8-K filing with the SEC. Charles River Laboratories’ common stock trades on the New York Stock Exchange under the symbol CRL.
In other recent news, Charles River Laboratories reported its third-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.43 compared to the forecast of $2.34. The company’s revenue also exceeded predictions, reaching $1 billion. Despite these positive financial results, concerns over organic revenue decline and operating margin contraction were noted. Additionally, Baird upgraded Charles River Labs from Neutral to Outperform, raising its price target to $199.00 from $178.00, citing long-term growth potential despite acknowledging a challenging quarter. In contrast, TD Cowen lowered its price target for Charles River Labs to $197.00 from $205.00, while maintaining a Buy rating, following a strategic review update that suggested a full Manufacturing sale is unlikely. These developments highlight a mixed outlook for the company, with varying analyst perspectives on its future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.